Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 1/20 | 0.58 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 4/20 | 0.55 |
| ▸ | CA9 | Q16790 | 4/20 | 0.55 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.55 |
| ▸ | FLT3 | P36888 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 3/20 | 0.47 |
| ▸ | MAOB | P27338 | 3/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | CASP1 | P29466 | 2/20 | 0.46 |
| ▸ | CASP7 | P55210 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10926839 | 0.85 | CA9 (0.56) | PDE3BPDE3ACA12CA9MCL1 | |
| SCHEMBL542111 | 0.78 | PDE3B (0.58) | PDE3BPDE3ACA12CA9MAOA | |
| SCHEMBL3922666 | 0.78 | PDE3B (0.58) | PDE3BPDE3ACA12CA9MAOB | |
| SCHEMBL182523 | 0.78 | PDE3B (0.58) | PDE3BPDE3ACA12CA9FLT3 | |
| SCHEMBL531587 | 0.77 | PDE3A (0.54) | PDE3BPDE3AMAOAKDM4ETDP1 | |
| SCHEMBL8800213 | 0.74 | PDE3B (1.00) | PDE3BPDE3ACA12CA9MAOB | |
| SCHEMBL182799 | 0.73 | PDE3B (0.53) | PDE3BPDE3ACA12CA9MCL1 | |
| SCHEMBL6938 | 0.72 | PDE3B (0.51) | PDE3BPDE3ACA12CA9MCL1 | |
| Hydrochloric Acid SCHEMBL7394595 | 0.71 | PDE3B (0.50) | PDE3BPDE3ACA12CA9MCL1 | |
| SCHEMBL2919634 | 0.71 | PDE3B (0.50) | PDE3BPDE3ACA12CA9MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7354915-B2 | 6-amino-1,4-dihydro-benzo[d][1,3]oxazin-2-ones and analogs useful as progesterone receptor modulators | WYETH (US) | 2008-04-08 | — | — | US | disclosed |
| US-20070225281-A1 | 6-Amino-1,4-dihydro-benzo[d][1,3]oxazin-2-ones and analogs useful as progesterone receptor modulators | WYETH (US) | 2007-09-27 | — | — | US | disclosed |
| US-7247625-B2 | 6-amino-1,4-dihydro-benzo[d][1,3] oxazin-2-ones and analogs useful as progesterone receptor modulators | WYETH (US) | 2007-07-24 | — | — | US | disclosed |
| US-20050085470-A1 | 6-Amino-1,4-dihydro-benzo[d][1,3] oxazin-2-ones and analogs useful as progesterone receptor modulators | WYETH | 2005-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085470-A1 | 6-Amino-1,4-dihydro-benzo[d][1,3] oxazin-2-ones and analogs useful as progesterone receptor modulators | PGR, FSHR, GPR6 | PDE3B 3706/4885PDE3A 3745/4885CA12 2064/4885 |
| US-20070225281-A1 | 6-Amino-1,4-dihydro-benzo[d][1,3]oxazin-2-ones and analogs useful as progesterone receptor modulators | PGR, FSHR, GPR6 | PDE3B 3706/4885PDE3A 3745/4885CA12 2064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.